Article Versions Notes

Berrou J, Dupont M, Djamai H, Adicéam E, Parietti V, Kaci A, Clappier E, Cayuela J-M, Baruchel A, Paublant F, et al. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine. 2022; 11(22):6761. https://doi.org/10.3390/jcm11226761

Berrou, Jeannig, Mélanie Dupont, Hanane Djamai, Emilie Adicéam, Véronique Parietti, Anna Kaci, Emmanuelle Clappier, Jean-Michel Cayuela, André Baruchel, Fabrice Paublant, and et al. 2022. "Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)" Journal of Clinical Medicine 11, no. 22: 6761. https://doi.org/10.3390/jcm11226761

Berrou, J., Dupont, M., Djamai, H., Adicéam, E., Parietti, V., Kaci, A., Clappier, E., Cayuela, J. -M., Baruchel, A., Paublant, F., Prudent, R., Ghysdael, J., Gardin, C., Dombret, H., & Braun, T. (2022). Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine, 11(22), 6761. https://doi.org/10.3390/jcm11226761